Navigation Links
AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test
Date:3/11/2009

Partnership to validate enhanced version of DR-70 cancer test

TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today it has entered into a collaborative agreement with Mayo Clinic to conduct a clinical study for the validation of AMDL's next generation version of its US FDA-approved DR-70 (FDP) cancer test.

Through this validation study, AMDL and Mayo Clinic will perform clinical diagnostic testing to compare AMDL's DR-70 (FDP) cancer test with a newly developed, next generation test. The primary goal of the study is to determine whether AMDL's next generation DR-70 (FDP) test serves as a higher-performing test to its existing predicate test and can lead to improved accuracy in the detection of early-stage cancers. For US FDA regulatory approval on the new test, AMDL intends to perform an additional study to demonstrate the safety and effectiveness of the next generation test for monitoring colorectal cancer ("CRC"). The validation study will run for three months and final results are expected in the second or third quarter of 2009.

"These efforts will be a significant step in validating the efficacy of our next generation DR-70 test as a valuable tool for the monitoring of early stage cancers," commented Dr. Andrea Small-Howard, Vice President of Scientific Oversight, AMDL, Inc. "Working through this critical and necessary phase in our product development process brings us one step closer to defining a leadership position in the cancer testing arena."

Although one of the most commonly diagnosed cancers, CRC is the third most common cancer worldwide and the second leading cause of cancer deaths (irrespective of gender) in the United States. There were approximately 151,000 new cases diagnosed in the US in 2008, roughly 51,000 deaths due to the disease*, and almost half of all
'/>"/>

SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives
2. AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008
3. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
4. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
5. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires
6. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
7. AMDL, Inc. Announces Strategic Realignment
8. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
9. AMDL, Inc. Closes Private Placement of Convertible Notes
10. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
11. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Huge event with ... future pharma industry health, analysis and forecasting   ... the closing of its most successful show to date ... 2,500 exhibitors. Held this year in Paris ... key players from 140+ countries representing every step of ...
(Date:10/31/2014)... Jeffrey T. Manuel, assistant professor in Southern ... College of Arts and Sciences, is teaming up with ... alcohol-based fuels in Illinois. , “Farmers, researchers, ... to build Illinois’ biofuels industry for decades,” Manuel said. ... state's agricultural and business history. , “Fuel alcohol ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/30/2014)... -- Investor-Edge has initiated coverage on the ... Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. (NASDAQ: ... SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research ... http://investor-edge.com/register . On Wednesday, October 29, 2014, ... Dow Jones Industrial Average declined 0.18%, to finish the ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... March 16, Shire plc (LSE: SHP, NASDAQ: ... the U.S. District Court of the Southern District of,New ... three,of Shire,s patents: U.S. Patent No. 5,968,976 (",976 Patent"); ... (",465"). , The lawsuit was ...
... AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net ... for the three months ended December 31, 2008, compared with ... basic and diluted, for the three months ended December 31, ... loss was $345,000, or $0.02 per share basic and diluted, ...
... 16 Contamination by mycoplasmal organisms is an ... them ready sources of contamination, while rendering them ... white paper, examines how PCR mycoplasma tests ... minimizes testing delays and enable safe, high-volume biopharmaceutical ...
Cached Biology Technology:Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 3AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 4New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 2New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 3
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... in the living world compete with members of ... how much they invest into their competitive ability. ... get access to high-quality resources, while others seem ... the lower-quality resources that are left over for ... and human societies seems to fluctuate considerably over ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... HOUSTON (Dec. 5, 2013) A new method ... proteins may speed the process of novel drug design, ... combination of computational techniques and experimental data helped Rice ... have been hard to detect. The work ...
... CHAMPAIGN, Ill. A 115-million-year-old fossilized wasp from northeast Brazil ... organ through which it lays its eggs, looks a lot ... figs. The problem, researchers say, is that figs arose about ... report of the findings appears in the journal ...
... levers: miniaturized robots of the future will be "soft". , ... to mind are the tentacles of an octopus or the ... a crane or the inner workings of a watch. And ... organisms moving in water. The robots of the future will ...
Cached Biology News:Proteins' passing phases revealed 2Proteins' passing phases revealed 3Ancient 'fig wasp' lived tens of millions of years before figs 2'Soft' (and miniaturized) robots 2
... the ideal CO2 incubator for cell and ... embryos at or near body temperature. HERAcell ... needed to protect and grow your valuable ... incubation conditions ensure optimum culture growth. ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
...
... High Vacuum pumps deliver critical performance ... gas ballast control optimizes pump performance to ... glass allows for convenient checking of proper ... series of pumps is designed to work ...
Biology Products: